Bayer Advanced LLC

MATERIAL SAFETY DATA SHEET

BAYER ADVANCED LLC 1500 Urban Center Dr. Birmingham, AL 35242

TRANSPORTATION EMERGENCY:

CALL CHEMTREC: (800) 424-9300 DISTRICT OF COLUMBIA: (202) 483-7616

1. CHEMICAL PRODUCT IDENTIFICATION:

PRODUCT NAME: BAYER AG Powerforce Kills Bugs Fast Multi-Insect

Killer Conc.

PRODUCT CODE: 41631
CHEMICAL FAMILY: Pyrethroid

CHEMICAL NAME: Cyano(4-fluoro-3-phenoxyphenyl)methyl 3-(2,2-

dichloro- ethenyl)-2,2-dimethylcyclopropanecarboxylate

SYNONYMS: Cyfluthrin

FORMULA: C22 H18 Cl2 F N 03
PRODUCT USE: Consumer Insecticide

2. COMPOSITION/INFORMATION ON INGREDIENTS:

INGREDIENT NAME

/CAS NUMBER EXPOSURE LIMITS CONCENTRATION (%)

***** HAZARDOUS INGREDIENTS *****

Cyfluthrin

68359-37-5 OSHA: Not Established 0.75%

ACGIH: Not Established

Ingredient 1510

Specific chemical identity is withheld as a trade secret.

OSHA: Not Established 1-2%

ACGIH: Not Established

3. HAZARDS IDENTIFICATION:

EMERGENCY OVERVIEW CAUTION!

Color: Off-white; Form: Liquid; Opaque aqueous emulsion; Odor: Trace odor of paint thinner; Harmful if inhaled or ingested; Causes eye irritation

POTENTIAL HEALTH EFFECTS:

ROUTE(S) OF ENTRY: Inhalation; Skin Contact; Eye Contact HUMAN EFFECTS AND SYMPTOMS OF OVEREXPOSURE:

ACUTE EFFECTS OF EXPOSURE: Exposure during the labeled use of this product is expected to be minimal. Consumers should refer to the packaging label for proper handling procedures. Sufficient exposures to cyfluthrin, the active ingredient in this product, may cause eye or skin irritation characterized by redness or itching. In addition, sufficient exposure to cyfluthrin may produce paraesthesia, a tingling or burning sensation on the surface of the skin. This is a frequently reported symptom associated with sufficient dermal exposure to alpha-cyano (or Type II) synthetic pyrethroids and normally subsides without treatment within 24 hours. The onset of these symptoms usually occurs 2-12 hours after exposure. Mucous membrane irritation involving the nose, throat and upper respiratory tract may occur from inhalation of aerosols containing cyfluthrin. Based on EPA Toxicity Category criteria, this product is mildly toxic by the oral and dermal routes of exposure. In addition, animal studies from a similar formulation of this material showed that it may cause skin sensitization.

NON-TRANSPORTATION:

BAYER EMERGENCY PHONE: (877) 229-3763 BAYER INFORMATION PHONE: (877) 229-3724

HAZARDS IDENTIFICATION (Continued):

CHRONIC EFFECTS OF EXPOSURE: Based on animal studies, no adverse effects are expected from chronic exposure to this product.

CARCINOGENICITY: This product is not listed by NTP, IARC or regulated as a carcinogen by OSHA.

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: No specific medical conditions are known which may be aggravated by exposure to the active ingredients in this product. As with all materials which can cause upper respiratory tract irritation, persons with a history of asthma, emphysema, or hyperreactive airway disease may be more susceptible to a response at low concentration.

4. FIRST AID MEASURES:

FIRST AID FOR EYES: Hold eyelids open and flush with plenty of water for 15 minutes. Call a physician if irritation persists or develops after flushing.

FIRST AID FOR SKIN: Remove contaminated clothing. Wash skin with soap and water. Get medical attention if irritation develops or persists.

FIRST AID FOR INHALATION: If a person is overcome by excessive exposures to this material, remove to fresh air or uncontaminated area. If not breathing, give artificial respiration, preferably mouth-to-mouth. Get medical attention as soon as possible.

FIRST AID FOR INGESTION: If ingestion is suspected, call a physician or poison control center. Drink one or two glasses of water and induce vomiting by touching back of throat with finger, or, if available, by administering syrup of ipecac. If syrup of ipecac is available, administer 1 tablespoonful (15 mL) of syrup of ipecac followed by 1 to 2 glasses of water. If vomiting does not occur within 20 minutes, repeat the dose once. Do not induce vomiting or give anything by mouth to an unconscious person.

NOTE TO PHYSICIAN: Treat the patient symptomatically. Published data indicate vitamin E acetate can prevent and/or mitigate symptoms of paraesthesia caused by synthetic pyrethroids.

5. FIRE FIGHTING MEASURES:

FLASH POINT: Greater than 230°F (110°C)
EXTINGUISHING MEDIA: Foam; Dry Chemical

SPECIAL FIRE FIGHTING PROCEDURES: Keep out of smoke. Cool exposed containers with water spray. Fight fire from upwind position. Use self-contained breathing equipment. Contain runoff by diking to prevent entry into sewers or waterways. Equipment or materials involved in pesticide fires may become contaminated.

6. ACCIDENTAL RELEASE MEASURES:

SPILL OR LEAK PROCEDURES: Isolate area and keep unauthorized people away. Do not walk through spilled material. Avoid breathing vapors and skin contact. Remove sources of ignition if combustible or flammable vapors may be present and ventilate area. Wear proper

ACCIDENTAL RELEASE MEASURES (Continued):

SPILL OR LEAK PROCEDURES (continued):

protective equipment. Dike contaminated area with absorbent granules, soil, sand, etc. If large spill, material should be recovered. Small spills can be absorbed with absorbent granules, spill control pads, or any absorbent materials. Carefully sweep up absorbed spilled material. Place in covered container for reuse or disposal. Scrub contaminated area with detergent and bleach solution and/or detergent and lye in water solution. Repeat. Rinse with water. Use dry absorbent material such as clay granules to absorb and collect wash solution for proper disposal. Contaminated soil may have to be disposed. Do not allow material to enter streams, sewers, or other waterways or contact vegetation.

7. HANDLING AND STORAGE:

STORAGE TEMPERATURE(MIN/MAX): None/30 day average not to exceed 38°C (100°F)

SHELF LIFE: Time/temperature-dependent. Specific information is available

on request.

SPECIAL SENSITIVITY: Not established

HANDLING/STORAGE PRECAUTIONS: Do not allow product to contaminate any material which is intended for use or consumption by humans or animals.

8. PERSONAL PROTECTION:

REQUIRED WORK/HYGIENE PROCEDURES: Exposure during the labeled use of this product is expected to be minimal. Consumers should refer to the packaging label for proper handling procedures. However, if exposure to this product is possible while handling large quantities such as in subsequent manufacturing, transportation spills or other emergencies, the following personal protection is recommended.

EYE PROTECTION REQUIREMENTS: Splash-proof goggles

SKIN PROTECTION REQUIREMENTS: Long sleeves and trousers

HAND PROTECTION REQUIREMENTS: Chemical-resistant gloves such as latex or nitrile

VENTILATION REQUIREMENTS: Control exposure levels through the use of general and local exhaust ventilation.

RESPIRATOR REQUIREMENTS: If needed, based on the conditions of use, wear a NIOSH-approved organic vapor respirator with particulate pre-filter.

ADDITIONAL PROTECTIVE MEASURES: Clean water and soap should be available for washing in case of eye or skin contamination. Educate and train employees in safe use of the product. Follow all label instructions. Launder clothing separately after use. Wash thoroughly after handling.

9. PHYSICAL AND CHEMICAL PROPERTIES:

PHYSICAL FORM: Liquid

APPEARANCE: Opaque aqueous emulsion

COLOR: Off-white

ODOR: Trace odor of paint thinner
MOLECULAR WEIGHT: 434.3 (for cyfluthrin)

pH: 3.5

BOILING POINT: Not established

MELTING/FREEZING POINT: Not established

VISCOSITY: 5 cps @ 20°C

SOLUBILITY IN WATER: Not established

SPECIFIC GRAVITY: 1.00 @ 20°C / 20°C

PHYSICAL AND CHEMICAL PROPERTIES (Continued):

BULK DENSITY: Not applicable

VAPOR PRESSURE: 7.2 x 10-9 mm Hg @ 20°C (for cyfluthrin)

10. STABILITY AND REACTIVITY:

STABILITY: This is a stable material.

HAZARDOUS POLYMERIZATION: Will not occur. INCOMPATIBILITIES: Alkaline or oxidizing media

INSTABILITY CONDITIONS: None known

DECOMPOSITION PRODUCTS: Not established

11. TOXICOLOGICAL INFORMATION:

Toxicity studies have not been performed on this product as formulated containing 0.75% of active ingredient, cyfluthrin. The acute toxicity data provided are from other cyfluthrin formulations. The acute eye irritation study has been performed on a formulation containing 0.1% active ingredient. All other acute toxicity data have been extrapolated from a formulation containing 24% active ingredient. The non-acute information pertains to cyfluthrin technical.

ACUTE TOXICITY:

ORAL LD50: Male Rat: 647 mg/kg; Female Rat: 695 mg/kg DERMAL LD50: Male and Female Rabbit: > 2000 mg/kg

INHALATION LC50: 4 HR Exposure to Liquid Aerosol: Male Rat: 0.716 mg/L (analytical); Female Rat: 0.924 mg/L (analytical) - 1 HR Exposure to Liquid Aerosol: Rat: >2.029 mg/L (analytical)

EYE EFFECTS: Rabbit: Minimal irritation to the conjunctiva was observed with all irritation clearing within 24 hours post-treatment.

SKIN EFFECTS: Rabbit: Moderate dermal irritant.

SENSITIZATION: Guinea pig: Positive dermal sensitizer.

SUBCHRONIC TOXICITY:

In a 3 week dermal toxicity study, cyfluthrin technical was administered to rats for 6 hours/day at dose levels of 100, 340 or 1000 mg/kg. Animals received a total of 17-18 applications in a period of 22-23 days. An additional control and high-dose group were treated and maintained for 14-15 days following treatment so as to ascertain the extent of recovery. Effects observed included reduced feed consumption, red nasal discharge, urine stains, and findings at the dose site (scabbing, crusty, discolored and raised zones). Histologically, epidermal and dermal alterations in treated skin were observed in animals of the mid- and high-dose groups. Similar, but slightly less severe microscopic alterations were also observed in the high-dose recovery group. The overall NOEL was 100 mg/kg. In a 13 week inhalation study, rats were exposed to cyfluthrin at aerosol concentrations of 0.09, 0.71 or 4.51 mg/m3 for 6 hours/day, 5 days/week. The NOEL was 0.09 mg/m3 based on reduced body weight gains.

CHRONIC TOXICITY:

Cyfluthrin has been investigated in chronic feeding studies using two different strains of rats. In each study, cyfluthrin was administered for 2 years at dietary concentrations ranging from 50 to 450 ppm. Body weight gains were decreased at concentrations of 150 ppm and greater. Changes in clinical chemistries occurred at 450 ppm. In one of the studies, histopathology revealed a numerical increase in mammary gland adenocarcinomas at 450 ppm. This finding was not statistically significant when compared to the controls and is not considered to be compound-related. In each study, the overall NOEL was 50 ppm based on decreased body weight gains. In a 1 year feeding study, dogs were administered cyfluthrin at dietary concentrations of 50, 100, 360 or 650 ppm. Beginning on week 8, the high dose was reduced to 500 ppm for the remainder of the study due to severe clinical neurological symptoms. Body weights were decreased for animals of the high-dose. Neurological findings (gait abnormalities and postural reaction deficits) were observed at doses of 360 and greater. The NOEL was 100 ppm.

TOXICOLOGICAL INFORMATION (Continued):

CARCINOGENICITY:

Cyfluthrin was investigated for carcinogenicity in chronic studies using several different strains of rats and mice. In rats, the maximum level tested was 450 ppm. Maximum levels tested in mice were 1400 and 1600 ppm for males and females, respectively. There was no evidence of a carcinogenic potential observed in any of the strains in either species.

MUTAGENICITY:

Numerous in vitro and in vivo mutagenicity studies have been conducted on cyfluthrin, all of which are negative.

DEVELOPMENTAL TOXICITY:

In developmental toxicity studies using rats, cyfluthrin was administered during gestation by oral gavage at doses ranging from 1 to 30 mg/kg. The overall NOEL from these studies for maternal toxicity was 3 mg/kg. No developmental effects were observed at any of the doses tested. In each study, the NOEL for developmental toxicity was equivalent to the highest dose tested. The NOELs for developmental toxicity for the initial study and the subsequent study were 30 and 10 mg/kg, respectively. Rabbits were administered cyfluthrin during gestation by oral gavage at doses ranging from 5 to 180 mg/kg. At maternally toxic levels, there was an increased incidence of post-implantation losses. The overall NOEL derived from these studies for both maternal and developmental toxicity was 20 mg/kg. In an inhalation study, rats were exposed during gestation to cyfluthrin at aerosol concentrations of 0.46, 2.55 or 11.9 mg/m3 for 6 hours/day. NOELs for maternal and developmental toxicity were less than 0.46 and 0.46 mg/m3, respectively.

REPRODUCTION:

In a reproduction study, cyfluthrin was administered to rats for 3 generations at dietary concentrations of 50, 150 and 450 ppm. Reproductive effects observed at parentally toxic levels included reductions in viability, lactation, litter size, feed consumption, and pup birth weights and body weight gains. Coarse tremors were observed in some offspring at 450 ppm. The NOEL for both parental and reproductive effects was 50 ppm. In another reproduction study, cyfluthrin was administered to rats for 2 generations at dietary concentrations of 50, 125 or 400 ppm. Coarse tremors occurring in conjunction with parental toxicity were observed in the offspring in the midand high-dose groups. Based on this finding, the neonatal NOEL was 50 ppm. The NOELs for parental and reproductive toxicity were 50 and 400 ppm, respectively.

NEUROTOXICITY:

Numerous neurotoxicity studies have been conducted on cyfluthrin. Oral gavage studies using hens have indicated that at extremely high dose levels (5000 mg/kg), minimal nerve damage occurs. When rats were administered cyfluthrin daily at oral doses of 40 to 80 mg/kg for 14 days, minimal nerve effects were seen. These effects were completely reversible within a 3 month recovery period. In dermal and inhalation studies which are more relevant to field exposure, there was no evidence of delayed neurotoxicity in hens. In a special investigative study, litters of neonatal mice (10 days of age) and their mothers were exposed to cyfluthrin via inhalation (whole body exposure). Mice were exposed to aerosol concentrations of 5, 15, or 50 mg/m3 for 6.3 hours/day for 7 successive days. Motor activity was measured in the offspring at 4 months of age (approximately 3.5 months post-exposure). At 50 mg/m3, all of the offsprings died or were sacrificed in a moribund state following the first exposure. Mortalities were not observed at any of the other levels. Clinical symptoms were observed immediately after exposure in young mice at 15 mg/m3, and included decreased motility, temporary scratching, and tonic convulsions. There was an increase in motor activity in mice at 15 mg/m3. Histopathological investigations did not reveal any treatment-related findings in mice at the age of 4 months.

12. ECOLOGICAL INFORMATION:

This product is toxic to fish and highly toxic to bees. Bayer will provide a summary of specific data upon written request. As with any pesticide, this product should be used according to label directions and should be kept out of

streams, lakes and other aquatic habitats of concern.

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHOD: Follow container label instructions for disposal of wastes generated during use in compliance with the FIFRA product label. In other situations, bury in an EPA-approved landfill or burn in an incinerator approved for pesticide destruction. Do not reuse container.

14. TRANSPORTATION INFORMATION:

TECHNICAL SHIPPING NAME: Cyfluthrin

FREIGHT CLASS BULK: Insecticides, NOI - NMFC

102100

FREIGHT CLASS PACKAGE: Insecticides, NOI - NMFC 102100

PRODUCT LABEL: Not Noted

DOT (DOMESTIC SURFACE)

HAZARD CLASS OR DIVISION: Non-Regulated

IMO / IMDG CODE (OCEAN)

HAZARD CLASS DIVISION NUMBER: Non-Regulated

ICAO / IATA (AIR)

HAZARD CLASS DIVISION NUMBER: Non-Regulated

15. REGULATORY INFORMATION:

OSHA STATUS: This product is hazardous under the criteria of the Federal OSHA Hazard Communication Standard 29 CFR 1910.1200.

TSCA STATUS: This product is exempt from TSCA Regulation under FIFRA Section 3 (2)(B)(ii) when used as a pesticide.

CERCLA REPORTABLE QUANTITY: None

SARA TITLE III:

SECTION 302 EXTREMELY HAZARDOUS SUBSTANCES: None

SECTION 311/312 HAZARD CATEGORIES: Immediate Health Hazard; Delayed Health Hazard

SECTION 313 TOXIC CHEMICALS: Cyfluthrin - 0.75% (CAS No. 68359-37-

RCRA STATUS: If discarded in its purchased form, this product would not be a hazardous waste either by listing or by characteristic. However, under RCRA, it is the responsibility of the product user to determine at the time of disposal, whether a material containing the product or derived from the product should be classified as a hazardous waste. (40 CFR 261.20-24)

16. OTHER INFORMATION:

NFPA 704M RATINGS:

Health 2 Flammability 1 Reactivity 0 Other 0=Insignificant 1=Slight 2=Moderate 3=High 4=Extreme Bayer's method of hazard communication is comprised of Product Labels and Material Safety Data Sheets. NFPA ratings are provided by Bayer as a customer service.

OTHER INFORMATION (Continued):

REASON FOR ISSUE: Revise Product Name

PREPARED BY: V. C. Standart

APPROVED BY: D. C. Eberhart

TITLE: Product Safety Manager

 APPROVAL DATE:
 06/15/2001

 SUPERSEDES DATE:
 10/15/1999

 MSDS NUMBER:
 32840

This information is furnished without warranty, expressed or implied, except that it is accurate to the best knowledge of Bayer Corporation. The data on this sheet relates only to the specific material designated herein. Bayer Corporation assumes no legal responsibility for use or reliance upon these data.